Charles River Laboratories Announces Second-Quarter 2017 Results from Continuing Operations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Charles River Laboratories (CRL) Tops Q2 EPS by 7c, Updates Guidance
August 9, 2017 7:06 AM EDTCharles River Laboratories (NYSE: CRL) reported Q2 EPS of $1.29, $0.07 better than the analyst estimate of $1.22. Revenue for the quarter came in at $469.1 million versus the consensus estimate of $458.03 million.
GUIDANCE:
Charles River Laboratories sees FY2017 EPS of $5.00-$5.15, versus the consensus of... More
